The Patent Finder

Treatment of Metastatic Pancreatic Adenocarcinoma

BioLineRx Ltd.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,291,570Treatment of Metastatic Pancreatic Adenocarcinoma
In force
 · High confidence
Biolinerx Ltd. and Merck Sharp & Dohme Corp.In forceHigh confidence
Application 18/109,281Treatment of Metastatic Pancreatic Adenocarcinoma
Pending
Not granted
Biolinerx Ltd. and Merck Sharp & Dohme Corp.PendingNot granted
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by BioLineRx Ltd..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited